Evidence map›Paper›PMID 42872106›Full record

ArticleCureus2026

A Family With Discordant Germline BRCA1 and BRCA2 Variants: A BRCA1-Positive Mother and BRCA2-Positive Daughter With Possible Paternal Inheritance.

Masahiro Kanamori, Hiroshi Adachi, Misa Kobayashi, Satoshi Hirakawa, Hiroharu Kobayashi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masahiro KanamoriObstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, JPN.
Hiroshi AdachiObstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, JPN.
Misa KobayashiObstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, JPN.
Satoshi HirakawaObstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, JPN.
Hiroharu KobayashiObstetrics and Gynecology, Seirei Hamamatsu General Hospital, Hamamatsu, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary breast and ovarian cancer (HBOC) is primarily caused by germline pathogenic variants in BRCA1 or BRCA2. Although a single pathogenic variant usually explains cancer predisposition within a family, independent pathogenic variants may coexist and complicate risk assessment and genetic counseling. We report a 43-year-old woman with right breast cancer in whom germline genetic testing identified a pathogenic BRCA2 variant, c.2808_2811del (p.Ala938ProfsTer21). Her mother developed primary peritoneal carcinoma at the age of 77. Tumor genomic testing identified a BRCA1 deletion of exons 1-12, which was subsequently confirmed as a germline variant. No pathogenic BRCA2 variant was detected in the mother. These discordant findings suggest that the daughter's BRCA2 variant may have been inherited through the paternal lineage or may have arisen de novo. The father was deceased and unavailable for genetic testing, and the paternal family history was uninformative. This case demonstrates that multiple independent BRCA pathogenic variants may coexist within a single family. Restricting cascade testing to a single known familial variant may therefore result in incomplete hereditary cancer risk assessment. Comprehensive germline evaluation and individualized, pedigree-based genetic counseling should be considered when clinical findings are discordant with a known familial variant.

Indexed as

brca1brca2cascade testinggermline testinghereditary cancerpaternal inheritanceprimary peritoneal carcinoma

Identifiers

PMID42872106
PMCPMC13660303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.